enVVeno Medical Corporation 's (NASDAQ:NVNO) share price dropped 2% during trading on Monday . The company traded as low as $5.83 and last traded at $5.84. Approximately 8,978 shares were traded  during trading, a decline of 74% from the average daily volume of 35,132 shares. The stock had previously closed at $5.96.

enVVeno Medical Trading Down 2.0 %

The stock has a 50 day simple moving average of $6.29 and a 200 day simple moving average of $5.48. The stock has a market cap of $55.32 million, a P/E ratio of -2.26 and a beta of 1.28.

Get enVVeno Medical alerts:

Institutional Investors Weigh In On enVVeno Medical

Large investors have recently modified their holdings of the business. Sepio Capital LP acquired a new stake in shares of  enVVeno Medical during the 2nd quarter valued at $41,000.  Dimensional Fund Advisors LP acquired a new stake in shares of  enVVeno Medical during the 3rd quarter valued at $135,000.  Arthur M. Cohen & Associates LLC boosted its holdings in shares of  enVVeno Medical by 60.0% during the 2nd quarter. Arthur M. Cohen & Associates LLC now owns 24,000 shares of the company's stock valued at $91,000 after acquiring an additional 9,000 shares in the last quarter.  UBS Oconnor LLC boosted its holdings in shares of  enVVeno Medical by 26.8% during the 3rd quarter. UBS Oconnor LLC now owns 149,720 shares of the company's stock valued at $940,000 after acquiring an additional 31,607 shares in the last quarter.  Finally, ACT Capital Management LLC boosted its holdings in shares of  enVVeno Medical by 52.8% during the 1st quarter. ACT Capital Management LLC now owns 401,200 shares of the company's stock valued at $2,556,000 after acquiring an additional 138,700 shares in the last quarter. Institutional investors and hedge funds own  22.65% of the company's stock.

enVVeno Medical Company Profile

(Get Rating)

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).

Read More

• Get a free copy of the StockNews.com research report on enVVeno Medical (NVNO)

• Santa Claus Rally? Here's What Needs to Happen

• Is Ardelyx is A Buy After Slip in Early 2022

• Will the Return of Bob Iger Return the Magic to Disney Stock?

• Is Tesla A Bargain Now As It Trades At Two-Year Lows?

• Black Friday Deals on These 3 Dividend Plays

Receive News & Ratings for enVVeno Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enVVeno Medical and related companies with MarketBeat.com's FREE daily email newsletter.